Synaptogenix Q1 2025 10-Q Filed
Ticker: TAOX · Form: 10-Q · Filed: May 15, 2025 · CIK: 1571934
| Field | Detail |
|---|---|
| Company | Synaptogenix, Inc. (TAOX) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Synaptogenix Q1 2025 10-Q: Assets $3.57K, Liabilities $4.28K, Cash $1.39M. Watch Series C Warrants.
AI Summary
Synaptogenix, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Neurotrope Bioscience, Inc., reported total assets of $3,570 and total liabilities of $4,285. It also disclosed cash and cash equivalents of $1,389,815 and total equity of $1,357,165. The filing references Series C Warrants and a September 2024 Private Placement.
Why It Matters
This filing provides a snapshot of Synaptogenix's financial health and operational details for the first quarter of 2025, including asset and liability figures.
Risk Assessment
Risk Level: low — The filing is a standard quarterly report with no immediate red flags or significant negative financial events indicated.
Key Numbers
- $3,570 — Total Assets (Financial position as of March 31, 2025)
- $4,285 — Total Liabilities (Financial position as of March 31, 2025)
- $1,389,815 — Cash and Cash Equivalents (Liquidity as of March 31, 2025)
- $1,357,165 — Total Equity (Net worth as of March 31, 2025)
Key Players & Entities
- Synaptogenix, Inc. (company) — Filer
- Neurotrope Bioscience, Inc. (company) — Former company name
- March 31, 2025 (date) — Reporting period end date
- $3,570 (dollar_amount) — Total assets
- $4,285 (dollar_amount) — Total liabilities
- $1,389,815 (dollar_amount) — Cash and cash equivalents
- $1,357,165 (dollar_amount) — Total equity
- September 2024 Private Placement (event) — Referenced financial activity
FAQ
What was Synaptogenix, Inc.'s total revenue for the quarter ending March 31, 2025?
The provided excerpt does not contain specific revenue figures for the quarter ending March 31, 2025.
What is the nature of the Series C Warrants mentioned in the filing?
The filing mentions Series C Warrants in relation to measurement inputs like risk-free interest rate, expected term, expected dividend rate, and estimated equity volatility, associated with a September 2024 Private Placement.
What was the company's net income or loss for the period?
The provided excerpt does not specify the net income or loss for the period ending March 31, 2025.
What are the primary business activities of Synaptogenix, Inc.?
Synaptogenix, Inc. is classified under Pharmaceutical Preparations (SIC code 2834), indicating its business involves the development and manufacturing of pharmaceutical products.
What were the company's total operating expenses for the quarter?
Specific figures for total operating expenses are not detailed in the provided excerpt.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Synaptogenix, Inc. (TAOX).